文献速递妇科生殖医学

瑞卢戈利(一种口服促性腺激素释放激素受体拮抗剂)以剂量依赖方式减轻子宫内膜异位症相关疼痛:一项随机、双盲、安慰剂对照研究

Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
PubMed 文献 · Fertil Steril · 2020-09-07

本项2期多中心随机双盲安慰剂对照研究纳入子宫内膜异位症相关疼痛的绝经前女性,比较瑞卢戈利10mg、20mg、40mg每日口服与安慰剂及亮丙瑞林3.75mg每月皮下注射的疗效与安全性。主要终点为治疗结束前28天盆腔痛视觉模拟量表评分较基线的变化,瑞卢戈利呈剂量依赖方式减轻疼痛,40mg疗效与安全性可比亮丙瑞林。

要点

  • 瑞卢戈利10mg、20mg、40mg组盆腔痛VAS评分较基线分别降低6.2、8.1、10.4mm,安慰剂组降低3.8mm。
  • 亮丙瑞林3.75mg组VAS评分较基线降低10.6mm,与瑞卢戈利40mg组相近。
  • 瑞卢戈利主要不良事件为潮热、经间期出血、月经过多、月经不规律及剂量依赖性骨密度下降,亮丙瑞林组也观察到类似事件。

核心结论

  • 口服瑞卢戈利以剂量依赖方式减轻子宫内膜异位症相关疼痛,总体耐受性良好。
  • 瑞卢戈利40mg的疗效与安全性与亮丙瑞林相当。

研究设计与样本

  • 2期、多中心、随机、双盲、安慰剂对照研究,在医院和诊所开展。
  • 受试者为有痛经和子宫内膜异位症相关盆腔痛的成年绝经前子宫内膜异位症女性。
  • 12周治疗期内,患者每日口服瑞卢戈利10mg(n=103)、20mg(n=100)或40mg(n=103),每日口服安慰剂(n=97),或每月皮下注射亮丙瑞林3.75mg(n=80)。
  • 主要终点为治疗结束前28天盆腔痛平均视觉模拟量表评分较基线的变化。

主要发现

  • 盆腔痛平均视觉模拟量表评分较基线变化:安慰剂组-3.8mm;瑞卢戈利10mg组-6.2mm、20mg组-8.1mm、40mg组-10.4mm;亮丙瑞林组-10.6mm。
  • 瑞卢戈利主要不良事件为潮热、经间期出血、月经过多和月经不规律,以及剂量依赖性骨密度下降。
  • 亮丙瑞林组也观察到上述不良事件,频率与瑞卢戈利40mg组相当。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of three dose levels of relugolix, a gonadotropin-releasing hormone receptor antagonist, compared with placebo and leuprorelin in women with endometriosis-associated pain. DESIGN: Phase 2, multicenter, randomized, double-blind, placebo-controlled study. SETTING: Hospitals and clinics. PATIENT(S): Adult premenopausal women with endometriosis who had dysmenorrhea and endometriosis-associated pelvic pain. INTERVENTION(S): During a 12-week treatment period, patients received relugolix 10 mg (n = 103), 20 mg (n = 100), or 40 mg (n = 103) as a daily oral dose; placebo (n = 97) as a daily oral dose; or leuprorelin 3.75 mg (n = 80) as a monthly subcutaneous injection. MAIN OUTCOME MEASURE(S): Primary endpoint was the change from baseline in mean visual analog scale score for pelvic pain during 28 days before the end of treatment. RESULT(S): The mean changes in mean visual analog scale score for pelvic pain were -3.8 mm in the placebo group; -6.2, -8.1, and -10.4 mm in the relugolix 10-mg, 20-mg, and 40-mg groups; respectively; and -10.6 mm in the leuprorelin group. The major adverse events with relugolix were hot flush, metrorrhagia, menorrhagia, and irregular menstruation, and bone mineral density decrease in a dose-response manner, which were also observed in the leuprorelin group with a frequency comparable with that in the relugolix 40-mg group. CONCLUSION(S): Oral administration of relugolix alleviated endometriosis-associated pain in a dose-response manner and was generally well tolerated. Relugolix 40 mg demonstrated efficacy and safety comparable with those of leuprorelin. CLINICAL TRIAL REGISTRATION NUMBER: NCT01458301.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Osuga Y, Seki Y, Tanimoto M, et al. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2020. PMID: 32912633. doi:10.1016/j.fertnstert.2020.07.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。